Prof. Xiaobing Chen 陈小兵
Chief Physician, Professor
Department of Integrated Traditional Chinese and Western Medicine Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for gastrointestinal, lung, and breast cancers. Expertise in maintenance, targeted, palliative, pain management, and nutritional support therapies.
Dr. Chen is a Professor and Chief Physician at Henan Cancer Hospital, holding a PhD in Oncology. Trained at the National Hospital in Oslo (2008) and attended programs at Harvard Medical School and Tsinghua University. Serves as Deputy Director of Internal Medicine. Research focuses on individualized drug therapy for colorectal, gastric, and lung cancers. Recognized as a national health science popularization expert.
Professional roles
- Member, Pancreatic Cancer Group and Palliative Care Group, Oncology Branch, Chinese Medical Association
- Standing Committee Member and Deputy Secretary-General, Science Popularization Professional Committee, China Anti-Cancer Association
- Standing Committee Member and Deputy Secretary-General, Patient Education Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Editorial Board Member, Chinese Journal of Colorectal Diseases (Electronic Edition)
Name order: in Chinese the family name comes first (Chen Xiaobing). Papers usually list the name as Xiaobing Chen or Chen X.
Selected publications
145 papers on PubMed matched by name and affiliation; 72 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Transl Oncol, 2026 (senior author): Molecular subtyping-guided precision therapy for ESCC: biomarker-driven strategies and clinical translation pathways. PubMed 41910707
- Gastroenterol Rep (Oxf), 2026 (senior author): Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer. PubMed 42542713
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Current research status and challenges of neoadjuvant immunotherapy for Esophageal squamous cell carcinoma. PubMed 41806941
- Funct Integr Genomics, 2026 (senior author): APLN, a novel prognostic biomarker, contributes to esophageal carcinoma development. PubMed 41499008
- Recent Pat Anticancer Drug Discov, 2026 (senior author): Resibufogenin and Oxaliplatin Synergistically Inhibit Diffuse Gastric Cancer by Inactivating the FAK/AKT/GSK3β/β-Catenin Signaling Pathway. PubMed 40129157
- Sci Rep, 2025 (senior author): Ifebemtinib and paclitaxel synergistically inhibit the proliferation and metastasis of TNBC by blocking PI3K/Akt pathway through LSD1/PIK3IP1 axis. PubMed 41315520
- Free Radic Biol Med, 2025 (senior author): BCAP31 promotes colorectal cancer metastasis via oxidative phosphorylation-dependent macrophage immunosuppression: A single-cell transcriptomic study. PubMed 40769312
- Biochim Biophys Acta Mol Basis Dis, 2025 (senior author): TRIM34 inhibits triple-negative breast cancer progression by attenuating fatty acid synthesis via facilitating FASN ubiquitination. PubMed 40543677
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion